Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins

Breast Cancer Research and Treatment

Volumn 154, Issue 3, 2015, Pages 623-631

  Göbel, Andy ^a   Browne, Andrew J ^a   Thiele, Stefanie ^a   Rauner, Martina ^a   Hofbauer, Lorenz C ^a,b   Rachner, Tilman D ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Breast cancer; Dickkopf 1; Mevalonate pathway; Osteoblasts; Statins; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; DICKKOPF 1 PROTEIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; OSTEOPROTEGERIN; ROSUVASTATIN; SIMVASTATIN; WNT3A PROTEIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DKK1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; SIGNAL PEPTIDE;

ALP GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DKK 1 GENE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OPG GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN GERANYLGERANYLATION; PROTEIN INDUCTION; PROTEIN PRENYLATION; PROTEIN SECRETION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; OSTEOBLAST; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATORVASTATIN CALCIUM; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEVALONIC ACID; MICE, NUDE; OSTEOBLASTS; ROSUVASTATIN CALCIUM; SIMVASTATIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948380673     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3624-8     Document Type: Article

References (31)

1. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593
2. Hofbauer LC, Rachner TD, Coleman RE, Jakob F (2014) Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol 2(June):500–512
3. Rachner TD, Göbel A, Benad-Mehner P, Hofbauer LC, Rauner M (2014) Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Lett 346:172–177
4. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483–2494
5. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET (2005) Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65:7554–7560
6. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y (2007) Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. Int J Cancer 2008(123):1034–1042
7. Forget M, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, Tanguay S, Lapointe R (2007) The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 96:646–653
8. Costa L (2007) Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 16:16–20
9. Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18:3524–3531
10. Demierre M-F, Demierre M-F, Higgins PDR, Higgins PDR, Gruber SB, Gruber SB, Hawk E, Hawk E, Lippman SM, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(December):930–942
11. Rachner TD, Göbel A, Thiele S, Rauner M, Benad-Mehner P, Hadji P, Bauer T, Muders MH, Baretton GB, Jakob F, Ebert R, Bornhäuser M, Schem C, Hofbauer LC (2014) Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Res 16:R20
12. Berndt N, Sebti SM (2011) Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nat Protoc 6:1775–1791
13. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16:1486–1495
14. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62:5571–5579
15. Rachner TD, Thiele S, Göbel A, Browne A, Fuessel S, Erdmann K, Wirth MP, Fröhner M, Todenhöfer T, Muders MH, Kieslinger M, Rauner M, Hofbauer LC (2014) High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer 14:649
16. Wilke M, Göbel A, Rauner M, Benad-Mehner P, Schütze N, Füssel S, Hadji P, Hofbauer LC, Rachner TD (2014) Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells. J Bone Oncol 3:10–17
17. Ageberg M, Rydström K, Lindén O, Linderoth J, Jerkeman M, Drott K (2011) Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. Exp Cell Res 317:1179–1191
18. Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ, Holen I (2010) Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? J Vasc Res 47:481–493
19. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P, Selander KS (2006) Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 12:2862–2868
20. Winter-Vann AM, Casey PJ (2005) Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 5(May):405–412
21. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG, Ghosh-Choudhury N (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286:11314–11327
22. Chan KKW, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10–19
23. Clézardin P (2012) Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bonekey Rep 2013(2):267
24. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, Garnero P (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97:964–970
25. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371–379
26. Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC (2014) A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167:366–375
27. Rachner TD, Göbel A, Junker M, Hötzel J, Benad-Mehner P, Hadji P, Hofbauer LC (2013) Regulation of VEGF by mevalonate pathway inhibition in breast cancer. J Bone Oncol 2:110–115
28. Van de Donk NWCJ, Kamphuis MMJ, Van Kessel B, Lokhorst HM, Bloem AC (2003) Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 102:3354–3362
29. Van De Donk NWCJ, Schotte D, Kamphuis MMJ, Van Marion AMW, Van Kessel B, Bloem AC, Lokhorst HM (2003) Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res 9:5735–5748
30. Zhu Y, Casey PJ, Kumar AP, Pervaiz S (2013) Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis 4:e568
31. Gronich N, Rennert G (2013) Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol 10:625–642